5-溴-3-氟-2-甲氧基苯胺 | 239122-51-1

• 物质功能分类: 有机原料 - 氨基化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 5-溴-3-氟-2-甲氧基苯胺
• 英文名称: 5-bromo-3-fluoro-2-methoxyaniline
• CAS: 239122-51-1
• 化学式: C₇H₇BrFNO
• 分子量: 220.041
• InChiKey: IRAJTRFSBJFFGT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存储条件：2-8°C，避光，并保存在惰性气体中。

反应信息

• 作为反应物：
  描述：

  5-溴-3-氟-2-甲氧基苯胺 在 盐酸 、 sodium nitrite 、 tin(ll) chloride 作用下， 以 水 为溶剂， 生成 (5-Bromo-3-fluoro-2-methoxyphenyl)hydrazine
  参考文献：
  名称：

  Discovery of 4-Aryl-7-Hydroxyindoline-Based P2Y₁ Antagonists as Novel Antiplatelet Agents

  摘要：

  Adenosine diphosphate (ADP)-mediated platelet aggregation is signaled through two distinct G protein-coupled receptors (GPCR) on the platelet surface: P2Y(12) and P2Y(1). Blocking P2Y(12) receptor is a clinically well-validated strategy for antithrombotic therapy. P2Y(1) antagonists have been shown to have the potential to provide equivalent antithrombotic efficacy as P2Y(12) inhibitors with reduced bleeding in preclinical animal models. We have previously reported the discovery of a potent and orally bioavailable P2Y(1) antagonist, I. This paper describes further optimization of 1 by introducing 4-aryl groups at the hydroxylindoline in two series. In the neutral series, 10q was identified with excellent potency and desirable pharmacokinetic (PK) profile. It also demonstrated similar antithrombotic efficacy with less bleeding compared with the known P2Y(12) antagonist prasugrel in rabbit efficacy/bleeding models. In the basic series, 20c (BMS-884775) was discovered with an improved PK and liability profile over 1. These results support P2Y(1) antagonism as a promising new antiplatelet target.

  DOI：

  10.1021/jm5006226
• 作为产物：
  描述：

  4-溴-2-氟-6-硝基苯甲醚 在 铁粉 、 溶剂黄146 作用下， 以 乙腈 为溶剂， 生成 5-溴-3-氟-2-甲氧基苯胺
  参考文献：
  名称：

  Substituted benzazoles and methods of their use as inhibitors of Raf kinase

  摘要：

  提供了新的替代苯唑化合物、组合物和抑制人类或动物主体中Raf激酶活性的方法。这些新化合物组合物可以单独使用，也可以与至少一种额外药物结合，用于治疗由Raf激酶介导的疾病，如癌症。

  公开号：

  US20040122237A1

文献信息

• [EN] COMT INHIBITORS<br/>[FR] INHIBITEURS DE COMT
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014102233A1

  公开（公告）日：2014-07-03

  The present invention relates to compounds of formula (I), wherein the substituents are described in claim 1 and to the pharmaceutically acceptable salts thereof. These compounds inhibit the enzyme catechol-O-methyltransferase (COMT). The compounds may be used for the treatment of Parkinson's disease, depression, cognitive impairment and motor symptoms, resistant depression, cognitive impairment, mood and negative symptoms of schizophrenia.

  本发明涉及式(I)的化合物，其中取代基如权利要求1所述，并且其药学上可接受的盐。这些化合物抑制酶儿茶酚-O-甲基转移酶(COMT)。这些化合物可用于治疗帕金森病、抑郁症、认知障碍和运动症状、抗抑郁症、认知障碍、情绪和精神分裂症的消极症状。
• [EN] IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS<br/>[FR] IMIDAZOPYRIDAZINECARBONITRILES POUVANT ÊTRE EMPLOYÉS EN TANT QU'INHIBITEURS DE KINASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2010042699A1

  公开（公告）日：2010-04-15

  The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazopyridazines inhibit protein kinase activity thereby making them useful as anticancer agents.

  该发明提供了式（I）的化合物及其药用可接受的盐。式（I）的咪唑吡啶嗪抑制蛋白激酶活性，因此使它们作为抗癌药物有用。
• [EN] COMPOSITIONS FOR USE IN METHODS OF INHIBITING PROTEIN KINASES<br/>[FR] COMPOSITIONS DESTINÉES À ÊTRE UTILISÉES DANS DES PROCÉDÉS D'INHIBITION DE PROTÉINES KINASES
  申请人：UNIV HOUSTON SYSTEM

  公开号：WO2018183633A1

  公开（公告）日：2018-10-04

  Identified compounds demonstrate protein kinase inhibitory activity and inhibition of dependent cell signaling pathways, such as NOD2 cell signaling. More specifically, the compounds are demonstrated to inhibit receptor interacting kinase 2 (RIPK2) and/or Activin- like kinase 2 (ALK2). Compounds that are either dual RIPK2/ALK2 inhibitors or that preferentially inhibit RIPK2 or ALK2 could provide therapeutic benefit.

  已确定的化合物表现出蛋白激酶抑制活性，并抑制依赖细胞信号通路，例如NOD2细胞信号传导。更具体地说，这些化合物被证明可以抑制受体相互作用激酶2（RIPK2）和/或Activin样激酶2（ALK2）。那些既是双重RIPK2/ALK2抑制剂，或者更倾向于抑制RIPK2或ALK2的化合物可能提供治疗益处。
• Receptor-interacting protein kinase 2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling inhibitors based on a 3,5-diphenyl-2-aminopyridine scaffold
  作者：Chalada Suebsuwong、Bing Dai、Daniel M. Pinkas、Anantha Lakshmi Duddupudi、Li Li、Joshua C. Bufton、Lisa Schlicher、Mads Gyrd-Hansen、Ming Hu、Alex N. Bullock、Alexei Degterev、Gregory D. Cuny

  DOI：10.1016/j.ejmech.2020.112417

  日期：2020.8

  kinase 2 (RIPK2) is a key mediator of nucleotide-binding oligomerization domain (NOD) cell signaling that has been implicated in various chronic inflammatory conditions. A new class of RIPK2 kinase/NOD signaling inhibitors based on a 3,5-diphenyl-2-aminopyridine scaffold was developed. Several co-crystal structures of RIPK2•inhibitor complexes were analyzed to provide insights into inhibitor selectivity

  受体相互作用蛋白激酶2（RIPK2）是核苷酸结合寡聚域（NOD）细胞信号传导的关键介体，已参与多种慢性炎症性疾病。基于3,5-二苯基-2-氨基吡啶骨架的新型RIPK2激酶/ NOD信号抑制剂被开发出来。分析了RIPK2•抑制剂复合物的几种共晶体结构，以了解抑制剂的选择性与结构相关的激活素受体样激酶2（ALK2）的关系，表明抑制剂位于RIPK2的疏水结合口袋中的位置更深，扰乱了DFG的方向主题。此外，结构-活性关系研究表明，除了分别通过2-氨基吡啶和3-苯基磺酰胺固定在铰链和DFG上，要实现有效的NOD细胞信号抑制，必须适当地占用网守和由3-苯基磺酰胺的4和5位上的取代基提供的αC-螺旋之间的区域。例如，化合物18t（例如CSLP37）在HEKBlue分析中显示出有效的生化RIPK2激酶抑制作用（IC 50  = 16±5 nM），相对于ALK2的选择性> 20倍和有效的NOD细胞信号传导抑制（IC
• IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS
  申请人：Fink Brian E.

  公开号：US20100113458A1

  公开（公告）日：2010-05-06

  The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazopyridazines inhibit protein kinase activity thereby making them useful as anticancer agents.

  该发明提供了式(I)的化合物及其药学上可接受的盐。式(I)的咪唑吡啶酮类化合物抑制蛋白激酶活性，因此可用作抗癌剂。